| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units | 29 | 2024 | 483 | 3.000 |
Why?
|
| Respiration, Artificial | 22 | 2021 | 458 | 2.850 |
Why?
|
| Hypertension, Pulmonary | 25 | 2013 | 434 | 2.230 |
Why?
|
| Critical Care | 19 | 2021 | 648 | 2.020 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2022 | 122 | 1.490 |
Why?
|
| Hospital Mortality | 11 | 2024 | 1010 | 1.270 |
Why?
|
| Pneumonia, Ventilator-Associated | 8 | 2014 | 41 | 1.260 |
Why?
|
| Hypnotics and Sedatives | 8 | 2022 | 135 | 1.220 |
Why?
|
| Lung Neoplasms | 17 | 2005 | 1593 | 1.180 |
Why?
|
| Conscious Sedation | 5 | 2015 | 63 | 1.040 |
Why?
|
| Patient Care Team | 5 | 2023 | 548 | 1.030 |
Why?
|
| Hypothermia, Induced | 2 | 2017 | 161 | 1.030 |
Why?
|
| Cross Infection | 6 | 2015 | 330 | 1.020 |
Why?
|
| Humans | 181 | 2025 | 123103 | 1.020 |
Why?
|
| Pneumonia | 7 | 2022 | 325 | 0.950 |
Why?
|
| Skin Tests | 4 | 2015 | 73 | 0.940 |
Why?
|
| Critical Illness | 7 | 2022 | 591 | 0.930 |
Why?
|
| Penicillins | 4 | 2015 | 154 | 0.910 |
Why?
|
| Education, Medical | 4 | 2019 | 289 | 0.900 |
Why?
|
| Lung Transplantation | 12 | 2007 | 316 | 0.890 |
Why?
|
| Drug Hypersensitivity | 4 | 2015 | 96 | 0.890 |
Why?
|
| Middle Aged | 76 | 2024 | 25992 | 0.890 |
Why?
|
| Hospitalization | 6 | 2024 | 1739 | 0.880 |
Why?
|
| Guideline Adherence | 4 | 2015 | 375 | 0.870 |
Why?
|
| Interdisciplinary Communication | 2 | 2014 | 134 | 0.840 |
Why?
|
| Leadership | 3 | 2023 | 230 | 0.810 |
Why?
|
| Patient-Centered Care | 2 | 2014 | 224 | 0.750 |
Why?
|
| Neuromuscular Blockade | 4 | 2021 | 5 | 0.750 |
Why?
|
| Internship and Residency | 5 | 2019 | 1158 | 0.740 |
Why?
|
| Negotiating | 1 | 2020 | 10 | 0.720 |
Why?
|
| Occupational Exposure | 2 | 2021 | 128 | 0.710 |
Why?
|
| Metabolic Syndrome | 1 | 2024 | 329 | 0.710 |
Why?
|
| Mindfulness | 1 | 2020 | 20 | 0.710 |
Why?
|
| Personal Protective Equipment | 1 | 2021 | 54 | 0.700 |
Why?
|
| Intubation, Intratracheal | 7 | 2022 | 291 | 0.690 |
Why?
|
| Male | 85 | 2024 | 60129 | 0.680 |
Why?
|
| Female | 94 | 2024 | 65514 | 0.670 |
Why?
|
| Policy | 1 | 2019 | 34 | 0.660 |
Why?
|
| Work Schedule Tolerance | 1 | 2019 | 38 | 0.660 |
Why?
|
| Adult | 63 | 2024 | 29009 | 0.660 |
Why?
|
| Shift Work Schedule | 1 | 2019 | 19 | 0.650 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 606 | 0.640 |
Why?
|
| Positive-Pressure Respiration | 9 | 2022 | 83 | 0.640 |
Why?
|
| Physicians | 4 | 2017 | 583 | 0.620 |
Why?
|
| Legionnaires' Disease | 2 | 2017 | 8 | 0.610 |
Why?
|
| Shock | 3 | 2022 | 90 | 0.610 |
Why?
|
| Bronchoscopy | 10 | 2014 | 153 | 0.600 |
Why?
|
| Aged | 49 | 2024 | 19093 | 0.600 |
Why?
|
| Ohio | 12 | 2010 | 86 | 0.580 |
Why?
|
| Education, Medical, Graduate | 2 | 2019 | 507 | 0.580 |
Why?
|
| Hypoxia | 4 | 2013 | 248 | 0.560 |
Why?
|
| Immunocompromised Host | 3 | 2014 | 295 | 0.560 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 45 | 0.550 |
Why?
|
| Thanatology | 1 | 2015 | 3 | 0.510 |
Why?
|
| Histamine | 1 | 2015 | 44 | 0.500 |
Why?
|
| Antihypertensive Agents | 6 | 2007 | 398 | 0.500 |
Why?
|
| Staphylococcal Infections | 4 | 2014 | 552 | 0.490 |
Why?
|
| Communication | 4 | 2023 | 513 | 0.490 |
Why?
|
| Infection Control | 2 | 2015 | 159 | 0.490 |
Why?
|
| Patient Rights | 1 | 2015 | 50 | 0.490 |
Why?
|
| Hand Hygiene | 1 | 2015 | 12 | 0.490 |
Why?
|
| Influenza, Human | 2 | 2022 | 648 | 0.480 |
Why?
|
| Neuromuscular Blocking Agents | 2 | 2008 | 6 | 0.480 |
Why?
|
| Hemolysin Proteins | 1 | 2014 | 31 | 0.470 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2014 | 220 | 0.470 |
Why?
|
| Legionella | 1 | 2014 | 9 | 0.470 |
Why?
|
| Prospective Studies | 27 | 2024 | 6028 | 0.470 |
Why?
|
| Respiratory Function Tests | 6 | 2007 | 195 | 0.460 |
Why?
|
| Personnel Staffing and Scheduling | 2 | 2011 | 78 | 0.460 |
Why?
|
| Terminal Care | 1 | 2015 | 113 | 0.460 |
Why?
|
| Diagnostic Errors | 3 | 2015 | 327 | 0.450 |
Why?
|
| Analgesics | 3 | 2015 | 134 | 0.440 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 175 | 0.440 |
Why?
|
| Staphylococcus aureus | 2 | 2014 | 455 | 0.430 |
Why?
|
| Oxygen | 4 | 2024 | 550 | 0.430 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 148 | 0.430 |
Why?
|
| Fellowships and Scholarships | 2 | 2017 | 271 | 0.430 |
Why?
|
| Pleural Diseases | 1 | 2013 | 29 | 0.430 |
Why?
|
| Risk Factors | 25 | 2024 | 10018 | 0.430 |
Why?
|
| APACHE | 8 | 2010 | 52 | 0.420 |
Why?
|
| Polymerase Chain Reaction | 2 | 2014 | 1584 | 0.420 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 2 | 2003 | 4 | 0.420 |
Why?
|
| Pleural Effusion | 3 | 2000 | 101 | 0.420 |
Why?
|
| Health Personnel | 4 | 2023 | 493 | 0.410 |
Why?
|
| Cause of Death | 6 | 2007 | 462 | 0.410 |
Why?
|
| Respiratory Insufficiency | 3 | 2011 | 231 | 0.410 |
Why?
|
| Health Surveys | 1 | 2013 | 241 | 0.400 |
Why?
|
| Retrospective Studies | 27 | 2022 | 16044 | 0.400 |
Why?
|
| Epoprostenol | 5 | 2007 | 67 | 0.380 |
Why?
|
| Palliative Care | 1 | 2015 | 428 | 0.380 |
Why?
|
| Pandemics | 5 | 2022 | 1101 | 0.380 |
Why?
|
| Pancoast Syndrome | 1 | 2011 | 3 | 0.380 |
Why?
|
| Sleep | 2 | 2007 | 348 | 0.370 |
Why?
|
| Monitoring, Physiologic | 3 | 2011 | 361 | 0.370 |
Why?
|
| Hypothyroidism | 2 | 2004 | 89 | 0.360 |
Why?
|
| Anti-Bacterial Agents | 7 | 2020 | 2393 | 0.360 |
Why?
|
| Aged, 80 and over | 17 | 2024 | 6374 | 0.350 |
Why?
|
| Carcinoma, Bronchogenic | 3 | 2002 | 6 | 0.350 |
Why?
|
| Algorithms | 7 | 2022 | 1598 | 0.350 |
Why?
|
| Intermittent Positive-Pressure Ventilation | 1 | 2010 | 8 | 0.350 |
Why?
|
| Methohexital | 1 | 2010 | 3 | 0.340 |
Why?
|
| Parasitic Diseases | 1 | 2011 | 62 | 0.340 |
Why?
|
| Etomidate | 1 | 2010 | 7 | 0.340 |
Why?
|
| Lung | 11 | 2022 | 1463 | 0.340 |
Why?
|
| Bronchiectasis | 1 | 2010 | 23 | 0.340 |
Why?
|
| Mycoses | 1 | 2011 | 116 | 0.340 |
Why?
|
| Anesthetics, Intravenous | 1 | 2010 | 47 | 0.340 |
Why?
|
| High-Frequency Ventilation | 3 | 2019 | 16 | 0.330 |
Why?
|
| Cohort Studies | 8 | 2024 | 4699 | 0.330 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2010 | 51 | 0.330 |
Why?
|
| Lung Diseases | 8 | 2005 | 378 | 0.330 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 141 | 0.330 |
Why?
|
| Prognosis | 12 | 2015 | 4512 | 0.330 |
Why?
|
| Paracentesis | 2 | 2000 | 17 | 0.320 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2000 | 23 | 0.320 |
Why?
|
| Smoking | 2 | 2004 | 1030 | 0.320 |
Why?
|
| Vasopressins | 2 | 2011 | 43 | 0.310 |
Why?
|
| Hematinics | 1 | 2009 | 57 | 0.310 |
Why?
|
| Point-of-Care Systems | 1 | 2011 | 170 | 0.310 |
Why?
|
| Erythropoietin | 1 | 2009 | 104 | 0.300 |
Why?
|
| Treatment Outcome | 15 | 2017 | 12115 | 0.300 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 2 | 2005 | 13 | 0.300 |
Why?
|
| Bacterial Infections | 1 | 2011 | 305 | 0.300 |
Why?
|
| Health Services Misuse | 2 | 2005 | 26 | 0.300 |
Why?
|
| Bacteremia | 4 | 2020 | 404 | 0.300 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2022 | 178 | 0.300 |
Why?
|
| Postoperative Complications | 5 | 2006 | 3011 | 0.290 |
Why?
|
| Opportunistic Infections | 3 | 2004 | 78 | 0.290 |
Why?
|
| Sulfonamides | 2 | 2006 | 259 | 0.290 |
Why?
|
| Scleroderma, Systemic | 3 | 2004 | 117 | 0.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2005 | 825 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 4 | 2005 | 1258 | 0.280 |
Why?
|
| Incidence | 13 | 2017 | 3039 | 0.280 |
Why?
|
| Nitric Oxide | 8 | 2008 | 439 | 0.280 |
Why?
|
| Medical Staff, Hospital | 2 | 2013 | 92 | 0.270 |
Why?
|
| Receptors, Immunologic | 1 | 2007 | 109 | 0.270 |
Why?
|
| Time Factors | 18 | 2014 | 6219 | 0.270 |
Why?
|
| Psychomotor Agitation | 2 | 2004 | 56 | 0.270 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2003 | 2055 | 0.270 |
Why?
|
| Insulin | 1 | 2011 | 1200 | 0.260 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2006 | 52 | 0.260 |
Why?
|
| Liver Cirrhosis | 2 | 2004 | 823 | 0.260 |
Why?
|
| Stereotyping | 1 | 2005 | 18 | 0.260 |
Why?
|
| Dyspnea | 2 | 1998 | 147 | 0.260 |
Why?
|
| Positive-Pressure Respiration, Intrinsic | 1 | 2005 | 2 | 0.260 |
Why?
|
| Fluid Therapy | 2 | 2022 | 121 | 0.260 |
Why?
|
| Enteral Nutrition | 1 | 2008 | 250 | 0.250 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2020 | 76 | 0.250 |
Why?
|
| Risk Assessment | 6 | 2015 | 3325 | 0.250 |
Why?
|
| Proteins | 1 | 2011 | 1037 | 0.250 |
Why?
|
| Wood | 1 | 2005 | 9 | 0.250 |
Why?
|
| Logistic Models | 9 | 2019 | 1797 | 0.250 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2005 | 36 | 0.250 |
Why?
|
| Patient Readmission | 2 | 2013 | 368 | 0.250 |
Why?
|
| Smoke | 1 | 2005 | 46 | 0.240 |
Why?
|
| Capnography | 1 | 2005 | 13 | 0.240 |
Why?
|
| Anemia | 1 | 2009 | 340 | 0.240 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 358 | 0.240 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 374 | 0.240 |
Why?
|
| Occult Blood | 1 | 2025 | 33 | 0.240 |
Why?
|
| Hand Disinfection | 2 | 2004 | 15 | 0.240 |
Why?
|
| Propylene Glycol | 1 | 2004 | 8 | 0.240 |
Why?
|
| Piperazines | 1 | 2006 | 230 | 0.240 |
Why?
|
| Lorazepam | 1 | 2004 | 12 | 0.240 |
Why?
|
| Body Fluids | 2 | 2006 | 47 | 0.240 |
Why?
|
| Solvents | 1 | 2004 | 42 | 0.230 |
Why?
|
| Continuity of Patient Care | 2 | 2019 | 154 | 0.230 |
Why?
|
| Pneumonectomy | 1 | 2005 | 129 | 0.220 |
Why?
|
| Preoperative Care | 2 | 2021 | 348 | 0.220 |
Why?
|
| Biopsy, Needle | 6 | 2004 | 229 | 0.220 |
Why?
|
| Sensitivity and Specificity | 8 | 2020 | 2011 | 0.220 |
Why?
|
| Treatment Refusal | 1 | 2004 | 77 | 0.220 |
Why?
|
| Length of Stay | 6 | 2017 | 1288 | 0.220 |
Why?
|
| Analgesics, Opioid | 1 | 2008 | 402 | 0.220 |
Why?
|
| Airway Resistance | 2 | 2005 | 36 | 0.220 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2003 | 9 | 0.220 |
Why?
|
| Eisenmenger Complex | 2 | 2004 | 5 | 0.220 |
Why?
|
| Serologic Tests | 2 | 2020 | 117 | 0.220 |
Why?
|
| Hyperhomocysteinemia | 1 | 2003 | 38 | 0.220 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2003 | 76 | 0.220 |
Why?
|
| Patients | 1 | 2004 | 121 | 0.220 |
Why?
|
| Survival Analysis | 8 | 2013 | 1473 | 0.210 |
Why?
|
| Oximetry | 4 | 2024 | 160 | 0.210 |
Why?
|
| Ventilators, Mechanical | 1 | 2003 | 35 | 0.210 |
Why?
|
| Nursing Staff, Hospital | 2 | 2000 | 60 | 0.210 |
Why?
|
| Metaphor | 1 | 2002 | 3 | 0.210 |
Why?
|
| Pilot Projects | 4 | 2022 | 1389 | 0.210 |
Why?
|
| Pulmonary Wedge Pressure | 5 | 2007 | 50 | 0.210 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2002 | 12 | 0.210 |
Why?
|
| Physician's Role | 1 | 2004 | 164 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 1071 | 0.200 |
Why?
|
| Empyema, Pleural | 3 | 1997 | 23 | 0.200 |
Why?
|
| Pulmonary Medicine | 1 | 2002 | 24 | 0.200 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2002 | 5 | 0.200 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2002 | 16 | 0.200 |
Why?
|
| Community-Acquired Infections | 2 | 2017 | 240 | 0.200 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2021 | 8 | 0.200 |
Why?
|
| Bronchoalveolar Lavage | 2 | 2014 | 24 | 0.190 |
Why?
|
| Motivational Interviewing | 1 | 2022 | 46 | 0.190 |
Why?
|
| Catheterization | 1 | 2003 | 235 | 0.190 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2005 | 419 | 0.190 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 41 | 0.190 |
Why?
|
| Clinical Competence | 3 | 2017 | 973 | 0.190 |
Why?
|
| Coccidioidomycosis | 1 | 2001 | 12 | 0.190 |
Why?
|
| Severity of Illness Index | 5 | 2015 | 2847 | 0.190 |
Why?
|
| Interprofessional Relations | 1 | 2022 | 144 | 0.180 |
Why?
|
| Lung Diseases, Fungal | 1 | 2001 | 32 | 0.180 |
Why?
|
| Prone Position | 2 | 2014 | 32 | 0.180 |
Why?
|
| Penicillin G | 1 | 2000 | 19 | 0.180 |
Why?
|
| Occupational Diseases | 1 | 2021 | 74 | 0.180 |
Why?
|
| Bronchoalveolar Lavage Fluid | 9 | 2010 | 151 | 0.180 |
Why?
|
| Autopsy | 1 | 2001 | 110 | 0.180 |
Why?
|
| Return to Work | 1 | 2020 | 12 | 0.180 |
Why?
|
| Hypotension | 1 | 2022 | 177 | 0.180 |
Why?
|
| Hyperthyroidism | 1 | 2000 | 26 | 0.180 |
Why?
|
| Disease Notification | 1 | 2020 | 7 | 0.180 |
Why?
|
| Triage | 1 | 2021 | 140 | 0.170 |
Why?
|
| Sarcoidosis | 2 | 1998 | 61 | 0.170 |
Why?
|
| Anaphylaxis | 1 | 2021 | 79 | 0.170 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 312 | 0.170 |
Why?
|
| Resuscitation Orders | 1 | 2000 | 32 | 0.170 |
Why?
|
| Texas | 7 | 2021 | 3563 | 0.170 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2000 | 25 | 0.170 |
Why?
|
| Bronchi | 3 | 2014 | 98 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 810 | 0.170 |
Why?
|
| Quality of Life | 5 | 2021 | 1923 | 0.170 |
Why?
|
| Silver Compounds | 2 | 2010 | 6 | 0.170 |
Why?
|
| Workplace | 1 | 2020 | 69 | 0.170 |
Why?
|
| Reproducibility of Results | 5 | 2024 | 2840 | 0.160 |
Why?
|
| Thrombophlebitis | 1 | 1999 | 22 | 0.160 |
Why?
|
| Self-Management | 1 | 2021 | 96 | 0.160 |
Why?
|
| Patient Admission | 1 | 2000 | 184 | 0.160 |
Why?
|
| Temperature | 1 | 2000 | 304 | 0.160 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 225 | 0.160 |
Why?
|
| Pulmonary Edema | 1 | 1999 | 49 | 0.160 |
Why?
|
| Surgeons | 1 | 2023 | 247 | 0.160 |
Why?
|
| Patient Education as Topic | 1 | 2002 | 449 | 0.160 |
Why?
|
| Radiopharmaceuticals | 1 | 2000 | 155 | 0.160 |
Why?
|
| Sleep Deprivation | 1 | 2019 | 50 | 0.160 |
Why?
|
| Feasibility Studies | 2 | 2022 | 756 | 0.160 |
Why?
|
| Mass Screening | 2 | 2025 | 786 | 0.160 |
Why?
|
| Colorectal Neoplasms | 1 | 2025 | 561 | 0.160 |
Why?
|
| Cystic Fibrosis | 3 | 2005 | 257 | 0.160 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 138 | 0.160 |
Why?
|
| Tidal Volume | 3 | 2021 | 39 | 0.160 |
Why?
|
| Asthma | 2 | 2005 | 744 | 0.160 |
Why?
|
| Patient Safety | 2 | 2021 | 394 | 0.160 |
Why?
|
| Albuterol | 1 | 1999 | 52 | 0.160 |
Why?
|
| Catheterization, Central Venous | 2 | 2014 | 132 | 0.150 |
Why?
|
| Workload | 1 | 2019 | 146 | 0.150 |
Why?
|
| Models, Statistical | 1 | 2001 | 470 | 0.150 |
Why?
|
| Pulmonary Artery | 4 | 2007 | 439 | 0.150 |
Why?
|
| History, 21st Century | 1 | 2019 | 269 | 0.150 |
Why?
|
| Patient Selection | 3 | 2013 | 683 | 0.150 |
Why?
|
| Emergency Service, Hospital | 1 | 2005 | 1075 | 0.150 |
Why?
|
| Endothelium, Vascular | 3 | 2007 | 514 | 0.150 |
Why?
|
| Heart Arrest | 1 | 2022 | 341 | 0.150 |
Why?
|
| History, 20th Century | 1 | 2019 | 381 | 0.150 |
Why?
|
| Medical Errors | 1 | 2019 | 155 | 0.150 |
Why?
|
| Burnout, Professional | 1 | 2019 | 114 | 0.140 |
Why?
|
| Syringes | 1 | 1997 | 24 | 0.140 |
Why?
|
| Prevalence | 6 | 2020 | 2395 | 0.140 |
Why?
|
| Antibodies, Viral | 2 | 2020 | 1138 | 0.140 |
Why?
|
| Age Factors | 1 | 2024 | 2799 | 0.140 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 263 | 0.140 |
Why?
|
| Young Adult | 5 | 2017 | 8855 | 0.140 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 473 | 0.140 |
Why?
|
| Brain Diseases | 1 | 2000 | 299 | 0.140 |
Why?
|
| Anti-Ulcer Agents | 1 | 1997 | 111 | 0.140 |
Why?
|
| Follow-Up Studies | 6 | 2013 | 5039 | 0.140 |
Why?
|
| Diagnosis, Differential | 5 | 2006 | 1876 | 0.140 |
Why?
|
| Lung Diseases, Interstitial | 1 | 1998 | 147 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 286 | 0.140 |
Why?
|
| Ventilator Weaning | 2 | 2008 | 23 | 0.140 |
Why?
|
| Adolescent | 14 | 2022 | 19094 | 0.140 |
Why?
|
| Peptic Ulcer | 1 | 1997 | 147 | 0.140 |
Why?
|
| Predictive Value of Tests | 6 | 2010 | 2112 | 0.140 |
Why?
|
| Pulmonary Embolism | 1 | 1999 | 174 | 0.140 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 195 | 0.140 |
Why?
|
| Metapneumovirus | 1 | 2017 | 51 | 0.140 |
Why?
|
| Burkholderia Infections | 1 | 1996 | 7 | 0.130 |
Why?
|
| Vaccines | 1 | 2021 | 370 | 0.130 |
Why?
|
| Airway Management | 1 | 2017 | 66 | 0.130 |
Why?
|
| Clinical Trials as Topic | 3 | 2011 | 1080 | 0.130 |
Why?
|
| Pregnancy Complications | 3 | 2005 | 507 | 0.130 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 1996 | 16 | 0.130 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1998 | 156 | 0.130 |
Why?
|
| Fiber Optic Technology | 2 | 2014 | 46 | 0.130 |
Why?
|
| United States | 6 | 2021 | 10651 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 2 | 2008 | 261 | 0.130 |
Why?
|
| Heparin | 1 | 1997 | 227 | 0.130 |
Why?
|
| Pleurisy | 1 | 2015 | 6 | 0.130 |
Why?
|
| Stress, Physiological | 1 | 1997 | 258 | 0.130 |
Why?
|
| Self Report | 2 | 2021 | 515 | 0.120 |
Why?
|
| Anesthesiology | 1 | 2017 | 93 | 0.120 |
Why?
|
| Time | 1 | 2015 | 94 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2000 | 641 | 0.120 |
Why?
|
| Academic Medical Centers | 2 | 2011 | 300 | 0.120 |
Why?
|
| Outpatients | 4 | 2007 | 254 | 0.120 |
Why?
|
| Quality Improvement | 3 | 2021 | 626 | 0.120 |
Why?
|
| Mexico | 1 | 2015 | 179 | 0.120 |
Why?
|
| Self-Evaluation Programs | 1 | 2014 | 2 | 0.120 |
Why?
|
| Case-Control Studies | 8 | 2022 | 3234 | 0.120 |
Why?
|
| Multiple Organ Failure | 4 | 2006 | 140 | 0.120 |
Why?
|
| Analgesia | 1 | 2015 | 44 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 4 | 2017 | 500 | 0.120 |
Why?
|
| Noninvasive Ventilation | 1 | 2015 | 30 | 0.120 |
Why?
|
| Tracheostomy | 2 | 2007 | 190 | 0.120 |
Why?
|
| Polysomnography | 2 | 2007 | 141 | 0.110 |
Why?
|
| Cardiomyopathies | 1 | 1998 | 478 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 2 | 2013 | 206 | 0.110 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 3664 | 0.110 |
Why?
|
| Catheters, Indwelling | 1 | 2014 | 155 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2019 | 1548 | 0.100 |
Why?
|
| Bias | 1 | 2013 | 124 | 0.100 |
Why?
|
| Postoperative Period | 4 | 2007 | 330 | 0.100 |
Why?
|
| Anticoagulants | 1 | 1997 | 581 | 0.100 |
Why?
|
| Catheter-Related Infections | 1 | 2014 | 131 | 0.100 |
Why?
|
| Disease Progression | 3 | 2022 | 2028 | 0.100 |
Why?
|
| Acute Disease | 3 | 2001 | 1093 | 0.100 |
Why?
|
| Phenylpropanolamine | 1 | 2011 | 4 | 0.100 |
Why?
|
| Professional Autonomy | 1 | 2011 | 27 | 0.100 |
Why?
|
| Equipment Contamination | 2 | 2010 | 38 | 0.100 |
Why?
|
| Biopsy | 3 | 2006 | 1236 | 0.100 |
Why?
|
| Internal Medicine | 1 | 2013 | 147 | 0.100 |
Why?
|
| Pneumonia, Bacterial | 3 | 2003 | 76 | 0.100 |
Why?
|
| Drug Resistance, Multiple | 2 | 2003 | 49 | 0.090 |
Why?
|
| Vasodilator Agents | 3 | 2003 | 203 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2011 | 317 | 0.090 |
Why?
|
| Nurse Practitioners | 1 | 2011 | 43 | 0.090 |
Why?
|
| Equipment Safety | 1 | 2011 | 37 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2011 | 3369 | 0.090 |
Why?
|
| Pneumococcal Infections | 1 | 2013 | 274 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2013 | 364 | 0.090 |
Why?
|
| NF-kappa B | 3 | 2002 | 457 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2006 | 1138 | 0.090 |
Why?
|
| Carrier State | 1 | 2010 | 76 | 0.090 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 1305 | 0.090 |
Why?
|
| Mentors | 2 | 2022 | 145 | 0.090 |
Why?
|
| Antioxidants | 3 | 2008 | 338 | 0.080 |
Why?
|
| Bacteriological Techniques | 1 | 2010 | 87 | 0.080 |
Why?
|
| Seasons | 2 | 2022 | 307 | 0.080 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2010 | 86 | 0.080 |
Why?
|
| Survival Rate | 3 | 2006 | 1999 | 0.080 |
Why?
|
| Epoetin Alfa | 1 | 2009 | 12 | 0.080 |
Why?
|
| Forced Expiratory Volume | 1 | 2010 | 169 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 1996 | 1001 | 0.080 |
Why?
|
| Students, Medical | 1 | 2013 | 361 | 0.080 |
Why?
|
| Hospital Costs | 1 | 2010 | 177 | 0.080 |
Why?
|
| Equipment Design | 1 | 2011 | 604 | 0.080 |
Why?
|
| Central Nervous System Diseases | 2 | 2000 | 105 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 510 | 0.080 |
Why?
|
| Gastrointestinal Contents | 1 | 2008 | 12 | 0.070 |
Why?
|
| Skin Care | 1 | 2008 | 14 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2000 | 426 | 0.070 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2008 | 52 | 0.070 |
Why?
|
| Abdomen, Acute | 1 | 2008 | 14 | 0.070 |
Why?
|
| Baths | 1 | 2008 | 16 | 0.070 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2008 | 70 | 0.070 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2014 | 621 | 0.070 |
Why?
|
| Biofilms | 1 | 2008 | 91 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 1386 | 0.070 |
Why?
|
| Obesity | 1 | 2019 | 2230 | 0.070 |
Why?
|
| Physician-Patient Relations | 2 | 2002 | 428 | 0.070 |
Why?
|
| Equipment Failure | 1 | 2008 | 122 | 0.070 |
Why?
|
| Withholding Treatment | 1 | 2008 | 67 | 0.070 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2007 | 7 | 0.070 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2007 | 25 | 0.070 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2007 | 42 | 0.070 |
Why?
|
| Blood Pressure Determination | 2 | 2005 | 105 | 0.070 |
Why?
|
| Biomarkers | 5 | 2013 | 2943 | 0.070 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2011 | 459 | 0.070 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2006 | 15 | 0.070 |
Why?
|
| Nutritional Requirements | 1 | 2008 | 177 | 0.070 |
Why?
|
| Blood Pressure | 4 | 2008 | 1325 | 0.070 |
Why?
|
| Vomiting | 1 | 2008 | 115 | 0.070 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2006 | 38 | 0.070 |
Why?
|
| Clinical Protocols | 2 | 2021 | 234 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2012 | 516 | 0.070 |
Why?
|
| Sildenafil Citrate | 1 | 2006 | 51 | 0.070 |
Why?
|
| Liquid Ventilation | 1 | 2006 | 1 | 0.070 |
Why?
|
| Sulfones | 1 | 2006 | 66 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2013 | 827 | 0.070 |
Why?
|
| Radiology | 1 | 2008 | 107 | 0.070 |
Why?
|
| Purines | 1 | 2006 | 107 | 0.070 |
Why?
|
| Radiography, Thoracic | 1 | 2006 | 152 | 0.060 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2006 | 35 | 0.060 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2008 | 223 | 0.060 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2005 | 6 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 2 | 2022 | 137 | 0.060 |
Why?
|
| Respiratory Dead Space | 1 | 2005 | 4 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 586 | 0.060 |
Why?
|
| Linear Models | 1 | 2007 | 669 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2004 | 1681 | 0.060 |
Why?
|
| Anesthesia, General | 1 | 2006 | 111 | 0.060 |
Why?
|
| Cytomegalovirus Infections | 2 | 1998 | 217 | 0.060 |
Why?
|
| Causality | 1 | 2005 | 83 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 151 | 0.060 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2005 | 37 | 0.060 |
Why?
|
| Central Venous Pressure | 1 | 2005 | 25 | 0.060 |
Why?
|
| Glycine | 1 | 2006 | 167 | 0.060 |
Why?
|
| ROC Curve | 1 | 2007 | 558 | 0.060 |
Why?
|
| Duodenoscopy | 1 | 2004 | 13 | 0.060 |
Why?
|
| Arginase | 1 | 2004 | 27 | 0.060 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 174 | 0.060 |
Why?
|
| Acid-Base Equilibrium | 1 | 2004 | 59 | 0.060 |
Why?
|
| Mental Competency | 1 | 2004 | 51 | 0.060 |
Why?
|
| Gastroscopy | 1 | 2004 | 102 | 0.060 |
Why?
|
| Exercise Test | 1 | 2005 | 249 | 0.060 |
Why?
|
| Evidence-Based Medicine | 2 | 2012 | 622 | 0.060 |
Why?
|
| Central Nervous System Depressants | 1 | 2004 | 23 | 0.060 |
Why?
|
| Electronics | 1 | 2004 | 42 | 0.060 |
Why?
|
| Observer Variation | 1 | 2005 | 300 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2006 | 1413 | 0.060 |
Why?
|
| Pentoxifylline | 1 | 2003 | 20 | 0.060 |
Why?
|
| Emotional Intelligence | 1 | 2023 | 13 | 0.050 |
Why?
|
| Health Care Rationing | 1 | 2003 | 58 | 0.050 |
Why?
|
| Esophagoscopy | 1 | 2004 | 156 | 0.050 |
Why?
|
| Acidosis | 1 | 2004 | 94 | 0.050 |
Why?
|
| Lactams | 1 | 2003 | 14 | 0.050 |
Why?
|
| Immunosuppressive Agents | 3 | 2002 | 642 | 0.050 |
Why?
|
| Vitamin B 12 | 1 | 2003 | 55 | 0.050 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2003 | 35 | 0.050 |
Why?
|
| Lung Injury | 1 | 2005 | 122 | 0.050 |
Why?
|
| Suction | 1 | 2003 | 58 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2003 | 140 | 0.050 |
Why?
|
| Forecasting | 1 | 2004 | 354 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 537 | 0.050 |
Why?
|
| Smoking Cessation | 1 | 2004 | 196 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2015 | 334 | 0.050 |
Why?
|
| Fertilization in Vitro | 1 | 2004 | 189 | 0.050 |
Why?
|
| Ammonia | 1 | 2003 | 68 | 0.050 |
Why?
|
| Sinusitis | 1 | 2003 | 117 | 0.050 |
Why?
|
| Pediatrics | 1 | 2011 | 1141 | 0.050 |
Why?
|
| Hepatic Encephalopathy | 1 | 2003 | 74 | 0.050 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2003 | 78 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2012 | 713 | 0.050 |
Why?
|
| Global Health | 1 | 2006 | 546 | 0.050 |
Why?
|
| Operating Rooms | 1 | 2022 | 71 | 0.050 |
Why?
|
| Occupational Health Services | 1 | 2021 | 6 | 0.050 |
Why?
|
| Fasting | 1 | 2003 | 297 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2004 | 279 | 0.050 |
Why?
|
| Endoscopy | 1 | 2003 | 282 | 0.050 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2022 | 118 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 348 | 0.050 |
Why?
|
| Creatinine | 1 | 2003 | 380 | 0.050 |
Why?
|
| Graft Survival | 1 | 2003 | 525 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2003 | 1439 | 0.050 |
Why?
|
| Nursing Assessment | 1 | 2001 | 26 | 0.050 |
Why?
|
| Endemic Diseases | 1 | 2001 | 57 | 0.050 |
Why?
|
| Nucleocapsid Proteins | 1 | 2020 | 4 | 0.050 |
Why?
|
| Benzeneacetamides | 1 | 2000 | 9 | 0.050 |
Why?
|
| Folic Acid | 1 | 2003 | 292 | 0.050 |
Why?
|
| Vancomycin Resistance | 1 | 2020 | 21 | 0.040 |
Why?
|
| Enterococcus | 1 | 2020 | 32 | 0.040 |
Why?
|
| Pleural Effusion, Malignant | 2 | 1997 | 14 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 593 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2022 | 229 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2002 | 270 | 0.040 |
Why?
|
| Breath Tests | 1 | 2001 | 179 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 422 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2001 | 355 | 0.040 |
Why?
|
| Monocytes | 1 | 2002 | 345 | 0.040 |
Why?
|
| Communicable Diseases | 1 | 2002 | 161 | 0.040 |
Why?
|
| Decision Trees | 1 | 2000 | 49 | 0.040 |
Why?
|
| Vasoconstriction | 1 | 2000 | 104 | 0.040 |
Why?
|
| Medical Futility | 1 | 2000 | 36 | 0.040 |
Why?
|
| Employment | 1 | 2020 | 67 | 0.040 |
Why?
|
| Travel | 1 | 2001 | 116 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2020 | 59 | 0.040 |
Why?
|
| Reference Standards | 1 | 2001 | 239 | 0.040 |
Why?
|
| Health Resources | 1 | 2001 | 115 | 0.040 |
Why?
|
| Inpatients | 2 | 2003 | 492 | 0.040 |
Why?
|
| Vascular Resistance | 1 | 2000 | 189 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 210 | 0.040 |
Why?
|
| Carcinoma, Small Cell | 1 | 2000 | 50 | 0.040 |
Why?
|
| Thyrotropin | 1 | 1999 | 58 | 0.040 |
Why?
|
| Down-Regulation | 3 | 2013 | 697 | 0.040 |
Why?
|
| Cell Count | 1 | 2000 | 250 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 117 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2000 | 105 | 0.040 |
Why?
|
| Macrophages, Alveolar | 1 | 1999 | 43 | 0.040 |
Why?
|
| Thyroxine | 1 | 1999 | 65 | 0.040 |
Why?
|
| Urinary Tract Infections | 1 | 2003 | 294 | 0.040 |
Why?
|
| Photopheresis | 1 | 1999 | 4 | 0.040 |
Why?
|
| Safety Management | 1 | 2020 | 110 | 0.040 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2001 | 145 | 0.040 |
Why?
|
| Decision Making | 1 | 2004 | 651 | 0.040 |
Why?
|
| Bronchography | 1 | 1999 | 4 | 0.040 |
Why?
|
| Bronchiolitis Obliterans | 1 | 1999 | 39 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2002 | 391 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 424 | 0.040 |
Why?
|
| Pheochromocytoma | 1 | 1999 | 33 | 0.040 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1999 | 36 | 0.040 |
Why?
|
| Acinetobacter Infections | 1 | 1999 | 25 | 0.040 |
Why?
|
| Medical Records | 1 | 1999 | 189 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 184 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2001 | 286 | 0.040 |
Why?
|
| Morbidity | 1 | 1999 | 241 | 0.040 |
Why?
|
| Vancomycin | 1 | 2020 | 218 | 0.040 |
Why?
|
| Macrophages | 1 | 2002 | 605 | 0.040 |
Why?
|
| Thrombophilia | 1 | 1998 | 40 | 0.040 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 1998 | 9 | 0.040 |
Why?
|
| Age Distribution | 1 | 1999 | 406 | 0.040 |
Why?
|
| Aspergillosis | 1 | 1998 | 43 | 0.040 |
Why?
|
| Pregnancy | 3 | 2005 | 7138 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2000 | 376 | 0.040 |
Why?
|
| Motor Activity | 1 | 2001 | 521 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 1290 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 769 | 0.040 |
Why?
|
| Needles | 1 | 1997 | 51 | 0.040 |
Why?
|
| Bronchodilator Agents | 1 | 1999 | 153 | 0.040 |
Why?
|
| Ethics, Medical | 1 | 2000 | 395 | 0.040 |
Why?
|
| Legionella pneumophila | 1 | 2017 | 6 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 1999 | 320 | 0.030 |
Why?
|
| Vaccination | 1 | 2022 | 944 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 1997 | 132 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 1999 | 162 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 1998 | 180 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 707 | 0.030 |
Why?
|
| Rheumatic Diseases | 1 | 1997 | 67 | 0.030 |
Why?
|
| Streptokinase | 1 | 1996 | 20 | 0.030 |
Why?
|
| Contraindications | 1 | 1996 | 77 | 0.030 |
Why?
|
| Hemothorax | 1 | 1996 | 22 | 0.030 |
Why?
|
| Eosinophilic Granuloma | 1 | 1996 | 3 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 1996 | 118 | 0.030 |
Why?
|
| Bronchoscopes | 1 | 1996 | 5 | 0.030 |
Why?
|
| Graft Rejection | 2 | 1999 | 582 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2000 | 334 | 0.030 |
Why?
|
| Child | 3 | 2023 | 24228 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 1996 | 75 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 1996 | 96 | 0.030 |
Why?
|
| Animals | 2 | 2014 | 33792 | 0.030 |
Why?
|
| Psychometrics | 1 | 2019 | 665 | 0.030 |
Why?
|
| Radiography | 1 | 1998 | 822 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2003 | 1015 | 0.030 |
Why?
|
| Cardiac Catheterization | 3 | 2007 | 631 | 0.030 |
Why?
|
| Medical History Taking | 2 | 2007 | 105 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 307 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2014 | 66 | 0.030 |
Why?
|
| Tuberous Sclerosis | 1 | 1996 | 121 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 1996 | 204 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 235 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 1997 | 485 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 1997 | 378 | 0.030 |
Why?
|
| Methods | 1 | 1993 | 145 | 0.030 |
Why?
|
| Superoxide Dismutase | 2 | 2008 | 139 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 1862 | 0.030 |
Why?
|
| Blood Buffy Coat | 1 | 2013 | 2 | 0.030 |
Why?
|
| Hemorrhage | 1 | 1997 | 458 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2014 | 192 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2014 | 173 | 0.030 |
Why?
|
| Teaching | 1 | 2014 | 183 | 0.030 |
Why?
|
| Therapeutic Irrigation | 1 | 1993 | 43 | 0.030 |
Why?
|
| Midazolam | 1 | 2013 | 49 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 1993 | 91 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2013 | 105 | 0.030 |
Why?
|
| Medical Audit | 1 | 2013 | 100 | 0.030 |
Why?
|
| Knowledge Bases | 1 | 2012 | 35 | 0.020 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1992 | 34 | 0.020 |
Why?
|
| Rest | 1 | 1992 | 59 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 1242 | 0.020 |
Why?
|
| Protein C | 2 | 2003 | 21 | 0.020 |
Why?
|
| Disease Management | 1 | 2015 | 514 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2013 | 312 | 0.020 |
Why?
|
| Ventricular Function, Right | 1 | 1992 | 112 | 0.020 |
Why?
|
| Models, Biological | 2 | 2008 | 1442 | 0.020 |
Why?
|
| Methicillin | 1 | 2010 | 43 | 0.020 |
Why?
|
| Mupirocin | 1 | 2010 | 19 | 0.020 |
Why?
|
| Medicaid | 1 | 2013 | 245 | 0.020 |
Why?
|
| Silver Sulfadiazine | 1 | 2010 | 9 | 0.020 |
Why?
|
| Nasal Cavity | 1 | 2010 | 48 | 0.020 |
Why?
|
| Gram-Positive Bacteria | 1 | 2010 | 46 | 0.020 |
Why?
|
| Hospital Charges | 1 | 2010 | 61 | 0.020 |
Why?
|
| Gram-Negative Bacteria | 1 | 2010 | 67 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2007 | 3040 | 0.020 |
Why?
|
| Registries | 2 | 2007 | 1394 | 0.020 |
Why?
|
| Bacterial Adhesion | 1 | 2010 | 107 | 0.020 |
Why?
|
| Lipopolysaccharides | 2 | 2002 | 292 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2012 | 306 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 280 | 0.020 |
Why?
|
| Rabbits | 1 | 2010 | 709 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 2010 | 116 | 0.020 |
Why?
|
| Cyclosporine | 2 | 2000 | 146 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 966 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2010 | 242 | 0.020 |
Why?
|
| Brain | 1 | 2000 | 2967 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1565 | 0.020 |
Why?
|
| Tyrosine | 1 | 2008 | 152 | 0.020 |
Why?
|
| Systole | 1 | 2008 | 196 | 0.020 |
Why?
|
| Research Design | 1 | 2012 | 676 | 0.020 |
Why?
|
| Respiratory Mucosa | 1 | 2008 | 91 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2008 | 235 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2010 | 381 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2002 | 1213 | 0.020 |
Why?
|
| beta-Lactams | 1 | 2007 | 50 | 0.020 |
Why?
|
| Cytokines | 2 | 2002 | 1284 | 0.020 |
Why?
|
| Voice | 1 | 2006 | 13 | 0.020 |
Why?
|
| Glycolysis | 1 | 2007 | 143 | 0.020 |
Why?
|
| Cardiac Output | 1 | 2006 | 169 | 0.020 |
Why?
|
| Bacteria | 1 | 2010 | 482 | 0.020 |
Why?
|
| Exercise | 1 | 1992 | 813 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2007 | 287 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 660 | 0.020 |
Why?
|
| Hydrostatic Pressure | 1 | 2005 | 8 | 0.020 |
Why?
|
| Transducers | 1 | 2005 | 25 | 0.020 |
Why?
|
| Carbon Monoxide | 1 | 2004 | 27 | 0.010 |
Why?
|
| Inservice Training | 1 | 2005 | 55 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2005 | 120 | 0.010 |
Why?
|
| Ketoconazole | 1 | 2003 | 10 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2005 | 211 | 0.010 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2003 | 52 | 0.010 |
Why?
|
| Organ Preservation | 1 | 2003 | 36 | 0.010 |
Why?
|
| Resource Allocation | 1 | 2003 | 52 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 2006 | 234 | 0.010 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2003 | 5 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2003 | 11 | 0.010 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2003 | 14 | 0.010 |
Why?
|
| Partial Pressure | 1 | 2003 | 28 | 0.010 |
Why?
|
| Vasomotor System | 1 | 2003 | 25 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2003 | 105 | 0.010 |
Why?
|
| Safety | 1 | 2004 | 218 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2003 | 145 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 2003 | 120 | 0.010 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2003 | 38 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 2003 | 113 | 0.010 |
Why?
|
| Mediastinoscopy | 1 | 2002 | 5 | 0.010 |
Why?
|
| Thorax | 1 | 2003 | 72 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 202 | 0.010 |
Why?
|
| Chemokine CCL3 | 1 | 2002 | 15 | 0.010 |
Why?
|
| Chemokine CCL4 | 1 | 2002 | 14 | 0.010 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2002 | 13 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 2003 | 77 | 0.010 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2002 | 51 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 2002 | 75 | 0.010 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2002 | 58 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2002 | 54 | 0.010 |
Why?
|
| Base Sequence | 1 | 2007 | 3091 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 600 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2002 | 84 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2002 | 113 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 250 | 0.010 |
Why?
|
| Mitochondria | 1 | 2007 | 677 | 0.010 |
Why?
|
| Waiting Lists | 1 | 2003 | 225 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2007 | 769 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1009 | 0.010 |
Why?
|
| Endosonography | 1 | 2002 | 81 | 0.010 |
Why?
|
| Interleukins | 1 | 2002 | 118 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2002 | 143 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2002 | 318 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2003 | 280 | 0.010 |
Why?
|
| Protein Transport | 1 | 2002 | 369 | 0.010 |
Why?
|
| Lung Volume Measurements | 1 | 2001 | 74 | 0.010 |
Why?
|
| Vital Capacity | 1 | 2001 | 76 | 0.010 |
Why?
|
| Spirometry | 1 | 2001 | 74 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 2001 | 82 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2003 | 258 | 0.010 |
Why?
|
| Respiratory Mechanics | 1 | 2001 | 75 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2002 | 393 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 469 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 411 | 0.010 |
Why?
|
| Nitroso Compounds | 1 | 1999 | 8 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2003 | 363 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 674 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 4283 | 0.010 |
Why?
|
| Paraganglioma | 1 | 1999 | 19 | 0.010 |
Why?
|
| Antithrombin III Deficiency | 1 | 1998 | 1 | 0.010 |
Why?
|
| Protein S Deficiency | 1 | 1998 | 2 | 0.010 |
Why?
|
| Protein C Deficiency | 1 | 1998 | 12 | 0.010 |
Why?
|
| Prothrombin | 1 | 1998 | 24 | 0.010 |
Why?
|
| Factor V | 1 | 1998 | 17 | 0.010 |
Why?
|
| Ceftazidime | 1 | 1999 | 41 | 0.010 |
Why?
|
| Exudates and Transudates | 1 | 1998 | 22 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2000 | 400 | 0.010 |
Why?
|
| Oxidants | 1 | 1998 | 25 | 0.010 |
Why?
|
| Glutathione Peroxidase | 1 | 1998 | 32 | 0.010 |
Why?
|
| Cephalosporins | 1 | 1999 | 138 | 0.010 |
Why?
|
| Homocysteine | 1 | 1998 | 121 | 0.010 |
Why?
|
| Confusion | 1 | 1998 | 16 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2003 | 939 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 1741 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2003 | 957 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1998 | 444 | 0.010 |
Why?
|
| Headache | 1 | 1998 | 108 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 1998 | 117 | 0.010 |
Why?
|
| Glutathione | 1 | 1998 | 193 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1999 | 665 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2003 | 996 | 0.010 |
Why?
|
| Attention | 1 | 1998 | 195 | 0.010 |
Why?
|
| Chest Tubes | 1 | 1996 | 36 | 0.010 |
Why?
|
| Laser Therapy | 1 | 1999 | 246 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1996 | 169 | 0.010 |
Why?
|
| Heart-Lung Transplantation | 1 | 1996 | 23 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1996 | 141 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 2809 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 1996 | 269 | 0.010 |
Why?
|
| Inflammation | 1 | 2002 | 1403 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2002 | 591 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1997 | 250 | 0.010 |
Why?
|
| Drainage | 1 | 1996 | 257 | 0.010 |
Why?
|
| Heart Failure | 1 | 2006 | 2128 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1996 | 1236 | 0.010 |
Why?
|
| Seizures | 1 | 1998 | 873 | 0.010 |
Why?
|
| Plants, Toxic | 1 | 1992 | 12 | 0.010 |
Why?
|
| Digitalis | 1 | 1992 | 3 | 0.010 |
Why?
|
| Theophylline | 1 | 1992 | 29 | 0.010 |
Why?
|
| Sympathomimetics | 1 | 1992 | 11 | 0.010 |
Why?
|
| Plants, Medicinal | 1 | 1992 | 23 | 0.010 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1992 | 91 | 0.010 |
Why?
|
| Ventricular Function | 1 | 1992 | 92 | 0.010 |
Why?
|
| Reference Values | 1 | 1992 | 697 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1998 | 3076 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1998 | 3545 | 0.000 |
Why?
|
| Mutation | 1 | 1998 | 5767 | 0.000 |
Why?
|